Dihydroergotamine Mesylate
FDA-approved product (injectable, injection), marketed as Atzumi, Brekiya (Autoinjector), D.h.e. 45 and 3 more.
- Registered studies
- 21
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Migraine disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Ergot alkaloids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
21registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dihydroergotamine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
NCT01468558 · start 2010-07
Registered record
- Registry ID
- NCT01468558
- Conditions
- Healthy
- Interventions
- MAP0004; IV DHE; Ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-07
- Completion
- 2010-08
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMAP0004; IV DHE; KetoconazolePhasePhase 1Registry statusCompletedPharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
NCT01089062 · start 2010-03
Registered record
- Registry ID
- NCT01089062
- Conditions
- Healthy
- Interventions
- MAP0004; IV Placebo (Saline); Placebo Inhaler; IV Dihydroergotamine Mesylate (DHE)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2010-12
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMAP0004; IV Placebo (Saline); Placebo Inhaler; IV Dihydroergotamine Mesylate (DHE)PhasePhase 1Registry statusCompletedPharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
NCT01199965 · start 2010-01
Registered record
- Registry ID
- NCT01199965
- Conditions
- Healthy Subjects
- Interventions
- MAP0004; IV DHE
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2010-01
- Completion
- 2010-04
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionMAP0004; IV DHEPhasePhase 1 / Phase 2Registry statusCompletedEffect of Dexamethasone on Migraine Headache
NCT00733382 · start 2008-02
Registered record
- Registry ID
- NCT00733382
- Conditions
- Migraine Headache
- Interventions
- dexamethazone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2008-02
- Completion
- 2009-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraine HeadacheInterventiondexamethazonePhasePhase 1Registry statusUnknownA Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
NCT00335777 · start 2006-08
Registered record
- Registry ID
- NCT00335777
- Conditions
- Migraine
- Interventions
- Migranal nasal spray at 1 hour; Migranal nasal spray at 4 hour
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2009-04
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraineInterventionMigranal nasal spray at 1 hour; Migranal nasal spray at 4 hourPhasePhase 4Registry statusCompletedA Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity
NCT00203268 · start 2003-12
Registered record
- Registry ID
- NCT00203268
- Conditions
- Migraine
- Interventions
- dihydroergotamine mesylate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2003-12
- Completion
- 2005-03
- Enrolment
- 13
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMigraineInterventiondihydroergotamine mesylatePhaseNot applicableRegistry statusCompleted